Abstract:Glucagon-stimulated hepatic gluconeogenesis contributes to endogenous glucose production during fasting. Recent studies suggest that TGF-β is able to promote hepatic gluconeogenesis in mice. However, the physiological relevance of serum TGF-β levels to human glucose metabolism and the mechanism by which TGF-β enhances gluconeogenesis remain largely unknown. As enhanced gluconeogenesis is a signature feature of type 2 diabetes, elucidating the molecular mechanisms underlying TGF-β-promoted hepatic gluconeogenesis would allow us to better understand the process of normal glucose production and the pathophysiology of this process in type 2 diabetes. This study aimed to investigate the contribution of upregulated TGF-β1 in human type 2 diabetes and the molecular mechanism underlying the action of TGF-β1 in glucose metabolism. Serum levels of TGF-β1 were measured by ELISA in 74 control participants with normal glucose tolerance and 75 participants with type 2 diabetes. Human liver tissue was collected from participants without obesity and with or without type 2 diabetes for the measurement of TGF-β1 and glucagon signalling. To investigate the role of Smad3, a key signalling molecule downstream of the TGF-β1 receptor, in mediating the effect of TGF-β1 on glucagon signalling, we generated Smad3 knockout mice. Glucose levels in Smad3 knockout mice were measured during prolonged fasting and a glucagon tolerance test. Mouse primary hepatocytes were isolated from Smad3 knockout and wild-type (WT) mice to investigate the underlying molecular mechanisms. Smad3 phosphorylation was detected by western blotting, levels of cAMP were detected by ELISA and levels of protein kinase A (PKA)/cAMP response element-binding protein (CREB) phosphorylation were detected by western blotting. The dissociation of PKA subunits was measured by immunoprecipitation. We observed higher levels of serum TGF-β1 in participants without obesity and with type 2 diabetes than in healthy control participants, which was positively correlated with HbA1c and fasting blood glucose levels. In addition, hyperactivation of the CREB and Smad3 signalling pathways was observed in the liver of participants with type 2 diabetes. Treating WT mouse primary hepatocytes with TGF-β1 greatly potentiated glucagon-stimulated PKA/CREB phosphorylation and hepatic gluconeogenesis. Mechanistically, TGF-β1 treatment induced the binding of Smad3 to the regulatory subunit of PKA (PKA-R), which prevented the association of PKA-R with the catalytic subunit of PKA (PKA-C) and led to the potentiation of glucagon-stimulated PKA signalling and gluconeogenesis. The hepatic TGF-β1/Smad3 pathway sensitises the effect of glucagon/PKA signalling on gluconeogenesis and synergistically promotes hepatic glucose production. Reducing serum levels of TGF-β1 and/or preventing hyperactivation of TGF-β1 signalling could be a novel approach for alleviating hyperglycaemia in type 2 diabetes.

Regulation of Hepatic Glucose Production by Transforming Growth Factor Beta 1 Via Protein Kinase A

Regulation Of Glucose Homeostasis And Lipid Metabolism By Ppp1r3g-Mediated Hepatic Glycogenesis

Upregulated TGF-β1 Contributes to Hyperglycaemia in Type 2 Diabetes by Potentiating Glucagon Signalling.

Reciprocal Regulation of Hepatic TGF-β1 and Foxo1 Controls Gluconeogenesis and Energy Expenditure

Transforming growth factor beta-1 upregulates glucose transporter 1 and glycolysis through canonical and noncanonical pathways in hepatic stellate cells

O-GlcNAc transferase/host cell factor C1 complex regulates gluconeogenesis by modulating PGC-1α stability.

Role of serum- and glucocorticoid-inducible kinase 1 in the regulation of hepatic gluconeogenesis.

Forkhead Box O1/Pancreatic and Duodenal Homeobox 1 Intracellular Translocation is Regulated by C-Jun N-Terminal Kinase and Involved in Prostaglandin E-2-Induced Pancreatic Beta-Cell Dysfunction

TGF-β1 Signaling Impairs Metformin Action on Glycemic Control

1303-P: Decreased Hepatic HMGB1 in Type 2 Diabetes Increases Mitochondrial Glucose Uptake by Regulating Insulin/AKT Signaling

Latent TGF-β1 Protects Against Diabetic Kidney Disease Via Arkadia/Smad7 Signaling

Angiopoietin-like Protein 8 (betatrophin) Inhibits Hepatic Gluconeogenesis Through PI3K/Akt Signaling Pathway in Diabetic Mice

Regulation of hepatic gluconeogenesis by nuclear factor Y transcription factor in mice

Direct Regulation of Glucose and Not Insulin on Hepatic Hexose-6-phosphate Dehydrogenase and 11Β-Hydroxysteroid Dehydrogenase Type 1

Hepatic p38α MAPK controls gluconeogenesis via FOXO1 phosphorylation at S273 during glucagon signalling in mice

Glucose Potentiates Beta-Cell Function by Inducing Tph1 Expression in Rat Islets

KLF10 transcription factor regulates hepatic glucose metabolism in mice

Novel Mechanism of Foxo1 Phosphorylation in Glucagon Signaling in Control of Glucose Homeostasis

Hepatic PTP4A1 ameliorates high-fat diet-induced hepatosteatosis and hyperglycemia by the activation of the CREBH/FGF21 axis

Transforming Growth Factor-Β1 Regulates the Nascent Hematopoietic Stem Cell Niche by Promoting Gluconeogenesis

Hepatic Traf2 Regulates Glucose Metabolism Through Enhancing Glucagon Responses